Polyamyna Nanotech Inc., headquartered in St. John's, Newfoundland and Labrador, is an innovative biotechnology company specializing in advanced antimicrobial technologies. The company focuses on addressing the critical global challenge of Antimicrobial Resistance (AMR), which renders conventional treatments ineffective against infections. Polyamyna's core mission is to develop new antibiotic drugs and technologies to combat multidrug-resistant (MDR) pathogens and prevent hospital-acquired infections (HAIs), which pose serious threats to public health by leading to prolonged hospital stays, increased healthcare costs, and even mortality.

Polyamyna serves a diverse range of clients, including healthcare institutions, research organizations, and government agencies. Operating in the biotechnology and healthcare markets, the company employs a business model centered on research and development (R&D), product innovation, and strategic partnerships. Revenue is generated through the commercialization of proprietary antimicrobial technologies, licensing agreements, and collaborative research projects.

The company’s interdisciplinary team comprises scientists, engineers, and professionals with extensive experience in real-world applications and management. This collective expertise enables Polyamyna to tackle complex challenges with a holistic approach. Additionally, the advisory board includes experts from various sectors, such as infectious diseases and defense, further strengthening the company's strategic direction.

Keywords: Antimicrobial, Biotechnology, Infection Prevention, AMR, MDR Pathogens, HAIs, Antibiotic Development, Healthcare, R&D, Innovation.